RFK Jr. is not a fan of weight-loss drugs or vaccines. Stocks are tanking.

Date:

November 15, 2024

The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs were sharply lower Friday, after President-elect Donald Trump named Robert F. Kennedy Jr. his pick to head the Department of Health and Human Services.

Source link

Heat Today: Bam Adebayo, rest of team eyes early solutions before facing Pacers

General Motors slashes another 1,000 jobs to cut costs

Alexandra Williams

Alexandra Williams is a writer and editor. Angeles. She writes about politics, art, and culture for LinkDaddy News.

RFK Jr. is not a fan of weight-loss drugs or vaccines. Stocks are tanking.

Recent posts

Cigna’s PBM Express Scripts sues the FTC, seeking retraction of drug-cost report

What’s next for bond markets after a week of wild volatility

Skydance reportedly accuses Paramount committee of violating merger deal

Commodity markets fear a repeat of China’s 2015 economic slowdown

Is gold’s record price run coming to an end? Here’s how to tell.

Trump crypto project: Why there’s ‘enormous potential downside’ for the campaign

‘DJT’ stock has seen ‘aggressive’ selling by retail investors leading into election

Chamber of Commerce calls on Biden to stop dockworkers strike, citing inflation fears

Tesla’s market cap hits $1 trillion after another Trump-fueled jump for the stock

These stocks offer some insulation against election volatility

Retiree healthcare costs jump almost 5% to $165,000 — more than double the 2002 rate

Trump’s proposed tariffs spark concerns for oil industry, even as the industry likes a lot of the Trump agenda

These stocks stand to benefit if a Trump White House adopts a tougher stance on China

A weak jobs report couldn’t stop 10-year Treasury yields from rising

A U.S. ‘sovereign wealth fund’? Please, no.

Related articles

Manufacturing activity surges in New York region to highest level in nearly three years

RFK Jr. would rattle health markets as head of HHS, but his confirmation is far from certain, analyst says

Vaccine-maker stocks like Moderna, Pfizer drop as Trump picks RFK Jr. to lead HHS

Powell says Fed doesn’t need to hurry to cut interest rates

Biogen’s stock rises after E.U. regulator reverses negative view of Alzheimer’s drug

Off-price retailers could thrive, BofA says, citing this bullish data point

Republicans clinch control of House, setting stage for quicker action on extending tax cuts

This biotech’s stock could double if its treatment for major depressive disorder succeeds, says Mizuho

Company

Follow us